Compounded GLP-1 Red Flags: What the FDA Says to Check Before You Inject It

Whether a compounded GLP-1 is legal for a given patient is a separate question from whether the specific vial in front of you is safe. We’ve covered the legal side elsewhere — brand vs. compounded, and why the shortage exemption is over. This piece is about the second question: the FDA maintains a running list of product-level problems it has found in compounded semaglutide and tirzepatide, and most of them are things a patient can actually check before injecting anything.

Fake pharmacies on real-looking labels

The FDA says it is aware of fraudulent compounded semaglutide and tirzepatide sold in the U.S. with false information on the product label. In some cases, the compounding pharmacy named on the label doesn’t exist at all. In others, the label carries the name of a real, licensed pharmacy that — according to the FDA’s own findings — never compounded that product. The agency has at least one adverse event report tied to this: a patient injected with a product labeled as compounded tirzepatide from a pharmacy that hadn’t actually made it, who developed redness, swelling, pain, and a red lump at the injection site. If a pharmacy name is printed on your vial, it’s worth confirming that pharmacy is licensed in Texas and will confirm, in writing, that it compounded your specific product.

The 28-day rule for multi-dose vials

Compounded GLP-1s are often dispensed in vials holding multiple doses for a patient to draw and self-inject over several weeks. The FDA’s general guidance for multi-dose sterile injectables is to discard the vial 28 days after first use, because contamination risk rises after that point — even if medication remains in the vial, and even if the compounder’s own instructions say it’s good for longer. The agency is explicit that a compounder’s label shouldn’t override that window. A new, sterile needle and syringe for every single dose is the other half of the same rule; reusing either raises contamination risk in the vial itself, not just at the injection site.

What a legitimate shipment looks like

Injectable GLP-1s require refrigeration, per their labeling. The FDA says it has received complaints about compounded GLP-1 shipments arriving warm or with inadequate ice packs, and its recommendation is unambiguous: don’t use an injectable GLP-1 that arrived warm or under-refrigerated, because heat exposure can degrade the drug before you ever draw a dose. Separately, the FDA has set up an import alert (Import Alert 66-80) aimed at GLP-1 active pharmaceutical ingredients entering the country with potential quality concerns — it doesn’t ban GLP-1 API imports outright, and doesn’t apply to manufacturers the FDA has found compliant, but it’s a sign the agency views the raw-ingredient supply chain, not just the finished product, as a real point of failure.

Dosing errors that led to hospitalization

The FDA has logged multiple adverse event reports — some requiring hospitalization — linked to dosing errors with compounded injectable semaglutide, including patients and, in some cases, clinicians miscalculating the correct dose. Separately, it has received reports tied to patients using compounded semaglutide or tirzepatide at doses or titration schedules beyond what’s on the FDA-approved label — more product per dose, more frequent doses, or a faster ramp-up than Wegovy, Ozempic, Zepbound, or Mounjaro’s own labeling allows. Reported symptoms have included nausea, vomiting, diarrhea, and abdominal pain serious enough that some patients sought medical care. None of that is a reason to assume every compounded product is mismeasured — it’s a reason to ask your prescriber to walk through the exact dose and schedule in writing, and to compare it against the brand product’s own label before you draw the syringe.

One category the FDA has already ruled out entirely

Two newer peptides sometimes marketed alongside semaglutide and tirzepatide — retatrutide and cagrilintide — aren’t a “check the label” situation at all. The FDA states plainly that neither can legally be compounded under federal law, for anyone, under any circumstance; they simply aren’t components of an FDA-approved drug. None of the clinics currently verified in our Houston directory list either one — if a clinic offers you retatrutide or cagrilintide as an injectable, that’s not a gray area to research further.

Before you accept the vial

Ask the clinic or telehealth platform, in writing: which pharmacy compounded this specific product, and can they confirm it? What’s the discard date on this vial, and does it match the 28-day rule? How was it shipped, and did it arrive cold? None of these questions require a medical degree to ask, and a compounder behaving the way the FDA expects will answer all three without hesitation.

See our full verification standard and browse verified GLP-1 and peptide clinics in Houston.

---

Source: U.S. Food and Drug Administration, “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss”, content current as of September 1, 2026.

This article is independent editorial content, not medical advice. See our medical disclaimer.